IQVIA Holdings Inc. $IQV Shares Acquired by Cullen Investment Group LTD.

Key Points

• Cullen Investment Group LTD. increased its stake in IQVIA Holdings Inc. by 21.4%, bringing its total investment to approximately $3.73 million with 23,651 shares owned.
• Analysts have shown strong confidence in IQVIA, with 18 analysts rating it as a 'Buy' and a consensus target price of $229.64.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, exceeding estimates, with a revenue of $4.02 billion, marking a 5.3% increase year-over-year.

Cullen Investment Group LTD. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,651 shares of the medical research company's stock after purchasing an additional 4,177 shares during the quarter. Cullen Investment Group LTD.'s holdings in IQVIA were worth $3,727,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Continuum Advisory LLC grew its stake in shares of IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after buying an additional 64 shares in the last quarter. Ballentine Partners LLC grew its position in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after acquiring an additional 69 shares in the last quarter. Independent Advisor Alliance increased its stake in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after purchasing an additional 72 shares during the period. ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Finally, Nemes Rush Group LLC increased its stake in IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after buying an additional 81 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Performance

IQV stock traded up $1.00 during trading on Tuesday, hitting $186.97. The company had a trading volume of 1,005,530 shares, compared to its average volume of 1,893,994. The firm has a market cap of $31.78 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $248.03. The firm has a 50-day moving average price of $183.32 and a 200-day moving average price of $167.24. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent research reports. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. Barclays lifted their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Jefferies Financial Group upgraded IQVIA from a "hold" rating to a "buy" rating and lifted their target price for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.